Wednesday, April 29, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 29, 2026
FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
background ▾
- •FDA has formally flagged concerns about camizestrant and Truqap in pre-advisory committee briefing documents, indicating substantive regulatory questions that require expert panel review
- •The advisory committee meeting represents a pivotal regulatory moment that could result in approval denial, conditional approval, restricted labeling, or requirements for additional data
- •Monitor the advisory committee meeting outcomes and any subsequent FDA communications regarding the nature of concerns and potential regulatory pathway for these oncology candidates
AstraZenecacamizestrantTruqap
→ Read original articlePolicy•STAT News•Apr 29, 2026
Opinion: Why alternative medicine can feel so much better than mainstream health care
background ▾
- •This is an opinion essay, not reporting on a regulatory decision, clinical trial, or market event—it reflects on systemic healthcare dissatisfaction but contains no actionable industry news
Policy•STAT News•Apr 29, 2026
In first meeting, federal autism committee focuses on ‘profound autism’
background ▾
- •IACC committee composition fundamentally altered to include vaccine-autism proponents despite lack of scientific evidence, potentially compromising federal autism research agenda worth hundreds of millions annually
- •Committee voted to change scientific definition of 'profound autism' and redirect resources toward this underserved population, but procedural violations and lack of public input undermine legitimacy
- •Watch whether Congress, NIH, and private research foundations (Simon's Foundation, Autism Speaks) will actually implement IACC guidance or distance themselves from the reformulated committee's recommendations
Policy•Fierce Pharma•Apr 29, 2026
Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies
background ▾
- •Novartis CEO publicly warns that existing European pricing policies threaten timely market access for new drugs, signaling escalating industry pushback against regional pricing constraints
- •The statement reflects broader pharma sector frustration with Europe's price regulation frameworks, which have tightened significantly and lag behind other developed markets
- •Monitor for coordinated industry advocacy efforts and potential regulatory responses from European health authorities and payers to pharma pricing complaints
Novartis
→ Read original articlePolicy•Fierce Pharma•Apr 29, 2026
FDA turns up heat on Amgen, proposing to rescind approval of Tavneos
background ▾
- •FDA proposes to withdraw Tavneos approval due to manipulated data in original submission and serious hepatotoxicity safety signals—a rare and severe regulatory action
- •This action raises questions about the adequacy of data integrity controls during the original approval process and Amgen's post-market safety monitoring
- •Watch for Amgen's formal response, potential clinical trial data re-examination, and whether the FDA issues a final rescission order or negotiates a settlement
AmgenTavneosavacopan
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 28, 2026
Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits
background ▾
- •Protagonist secures $200 million immediately plus $275 million contingent on FDA approval, with potential additional $975 million in milestones and 14-29% worldwide royalties—substantially improving risk-adjusted economics versus the original 50/50 split
- •Rusfertide's pivotal phase 3 success and January 2025 FDA submission triggered the opt-out window, indicating strong confidence in approval likelihood by Q3 2025
- •Watch for FDA approval decision in Q3 2025 and Takeda's commercial launch strategy for rusfertide in a PV market currently dominated by JAK inhibitors
Protagonist TherapeuticsTakeda Pharmaceuticalrusfertide
→ Read original articleMarket Access•Fierce Biotech•Apr 28, 2026
AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition
background ▾
- •AbbVie secures potential acquisition option for Kestrel's pan-KRAS program (KST-6051) via tiered $1.45B deal, establishing a foothold in the high-validation RAS inhibitor space without the reported $20B+ price tag needed for Revolution Medicines.
- •KST-6051 phase 1 dosing initiation positions Kestrel ahead of many pan-KRAS competitors; success here could validate Kestrel's multi-mutation KRAS approach versus single-mutation focused programs like Amgen's Lumakras.
- •Watch for KST-6051 phase 1 efficacy/safety readouts and whether AbbVie exercises acquisition option; also monitor Kestrel's ability to advance into phase 2 and compete against Revolution Medicines' daraxonrasib and other next-gen RAS inhibitors in clinical development.
AbbVieKestrel TherapeuticsAmgenKST-6051LumakrasVectibix
→ Read original articleMarket Access•Endpoints News•Apr 28, 2026
Pfizer delays patent cliff for blockbuster Vyndamax
background ▾
- •Vyndamax patent protection extended by ~2 years, deferring generic/biosimilar competition and protecting a top-3 Pfizer revenue generator
- •This is a material commercial event that preserves near-term revenue visibility for a blockbuster asset
- •Watch for generic/biosimilar launch timelines post-extension and any competitor litigation or regulatory filings that may affect the final exclusivity date
PfizerVyndamaxtafamidis
→ Read original articleMarket Access•Fierce Pharma•Apr 29, 2026
Rocket sells priority review voucher for $180M after Kresladi gene therapy approval
background ▾
- •Rocket generated $180M in cash by selling its pediatric rare disease PRV, a valuable regulatory asset granted upon Kresladi approval
- •The transaction reflects sustained high demand for FDA priority review vouchers among sponsors seeking expedited pathways for their pipeline programs
- •Remaining uncertainty centers on which therapeutic program will ultimately use the voucher and whether the acquiring company's timeline aligns with PRV expiration (typically 10 years)
Rocket PharmaceuticalsKresladi
→ Read original articleMarket Access•Fierce Biotech•Apr 28, 2026
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
background ▾
- •Lilly is investing heavily in recombinase-based gene editing as a strategic priority, committing $2.2B to Profluent alone plus $1.12B to Seamless Therapeutics for similar technology, signaling confidence in kilobase-scale DNA editing as a near-term therapeutic modality
- •Profluent's AI protein design platform and 115+ billion protein atlas have attracted both top-tier venture capital (Bezos Expeditions) and Big Pharma validation, positioning AI-designed biologics as a competitive advantage in gene editing
- •Watch for clinical development timelines and target selection; Lilly's deal velocity and capital deployment suggest potential IND filings within 2-3 years, making near-term pipeline announcements critical to validating this investment thesis
Eli LillyProfluentSeamless Therapeutics
→ Read original articleClinical Trials
Clinical Trials•Fierce Pharma•Apr 29, 2026
With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
background ▾
- •Kite is preparing for a next-generation multiple myeloma CAR-T approval decision expected later in 2024, with refined manufacturing strategies based on past market experience
- •The company has recalibrated its production approach to address previous bottlenecks and commercial challenges in CAR-T cell therapy distribution and scalability
- •Watch for the approval decision and initial market penetration metrics, as successful commercialization will depend on manufacturing reliability and payer reimbursement landscape
Gilead SciencesKite Pharma
→ Read original articleClinical Trials•Fierce Biotech•Apr 28, 2026
Erasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death
background ▾
- •ERAS-0015 met Erasca's pre-specified efficacy superiority benchmark against daraxonrasib with a 40% vs. 19.6% response rate in pancreatic cancer and 62% vs. 37.5% in lung cancer, with claimed advantages across five safety/tolerability attributes.
- •A patient death from pneumonitis—though attributed to withdrawal of supportive care rather than drug toxicity—drove significant market skepticism despite being a rare, manageable side effect of RAS-targeted therapies.
- •Revolution Medicines has threatened legal action for improper comparative claims; monitor phase 1b dose expansion and combination data (H1 2025) and any regulatory or intellectual property developments, as the competitive and legal landscape remains volatile.
ErascaRevolution MedicinesJoyo PharmatechERAS-0015daraxonrasib
→ Read original articleClinical Trials•Endpoints News•Apr 28, 2026
Incyte claims double Phase 3 win in vitiligo, will file for approval
background ▾
- •Povoricitinib achieved positive efficacy endpoints in two Phase 3 trials for non-segmental vitiligo, de-risking the regulatory path to approval
- •As an oral JAK1 inhibitor, povoricitinib could offer a convenient alternative to topical or systemic therapies in a treatment-limited indication
- •Monitor regulatory submission timing and competitive landscape (other JAK inhibitors or novel modalities in vitiligo)
Incytepovoricitinib
→ Read original article